Results 111 to 120 of about 88,593 (298)

Long‐term cardiovascular outcomes of immune checkpoint inhibitor‐related myocarditis: A large single‐centre analysis

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 1237-1245, April 2025.
Abstract Aims Immune checkpoint inhibitors (ICI) are the cornerstone of modern oncology; however, side effects such as ICI‐related myocarditis (irM) can be fatal. Recently, Bonaca proposed criteria for irM; however, it is unknown if they correlate well with cardiovascular (CV) ICI‐related adverse events.
Lorenzo Braghieri   +12 more
wiley   +1 more source

Partial Congenital Absence of The Pericardium: A Case Report

open access: yes, 2019
The complete or the partial absence of pericardium is a rare congenital malformation for which the patients are commonly asymptomatic and the diagnosis is incidental.
Narjes Benameur (6800432)   +5 more
core   +2 more sources

A phenomap of TTR amyloidosis to aid diagnostic screening

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 1113-1118, April 2025.
Abstract Cardiac amyloidosis due to transthyretin (ATTR) remains an underdiagnosed cause of cardiomyopathy. As awareness of the disease grows and referrals for ATTR increase, clinicians are likely to encounter more atypical forms of the condition in clinical practice.
Alexios S. Antonopoulos   +4 more
wiley   +1 more source

Exercise limitations in amyloid cardiomyopathy assessed by cardiopulmonary exercise testing—A multicentre study

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 1326-1335, April 2025.
Abstract Aims Amyloid cardiomyopathy is caused by the deposition of light chain (AL) or transthyretin amyloid (ATTR) fibrils, that leads to a restrictive cardiomyopathy, often resulting in heart failure (HF) with preserved or reduced ejection fraction.
Robin Willixhofer   +25 more
wiley   +1 more source

Mechanotransduction of autotransplants: remodeling potential of heart valves from autologous pericardial tissue

open access: yesFrontiers in Bioengineering and Biotechnology
Current commercial heart valve prostheses are non-living structures, either derived from artificial materials (mechanical valves) or foreign biological materials (xeno- or homo-graft).
Marvin Steitz   +15 more
doaj   +1 more source

Dapagliflozin alleviates high‐fat‐induced obesity cardiomyopathy by inhibiting ferroptosis

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 1358-1373, April 2025.
Abstract Aim: Dapagliflozin (Dapa) is a novel hypoglycaemic agent with multiple cardiovascular protective effects, and it is widely used in treatment of heart failure patients, but whether it can improve obese phenotype of heart failure and its mechanism is still unclear.
Di Chen   +7 more
wiley   +1 more source

CALCIFICATION OF CHEMICALLY TREATED BOVINE PERICARDIUM

open access: yes, 1991
One of the most important problems arising in cardiac bioprostheses made with bovine pericardium and, more generally, with biologically-derived tissues is tissue calcification.
M. GALLONI   +7 more
core   +1 more source

Glycosaminoglycan Stabilization in Bovine Pericardium

open access: yes, 2007
Glutaraldehyde crosslinked bovine pericardium has been used for fabrication of bioprosthetic heart valves as well as cardiac patches for soft tissue repair.
Browne, Lauren
core   +1 more source

Maternal and perinatal outcomes of pregnant women with echocardiographically high probability of pulmonary arterial hypertension

open access: yesInternational Journal of Gynecology &Obstetrics, EarlyView.
Abstract Objective This study aimed to describe maternal and perinatal outcomes among pregnant women with echocardiographically high probability of pulmonary arterial hypertension (PAH) managed at a quaternary center and to compare outcomes between women with and without cardiac complications (CC).
Laura Belmont‐Rojo   +6 more
wiley   +1 more source

Oligosaccharide Lactate Nanoparticles Enhance Tissue Targeting: A Case Study of the Controlled Delivery of Bedaquiline to Cardiac Tissue in TB Pericarditis

open access: yesMolecules
Bedaquiline is known to shorten the duration of therapy of tuberculosis but has limitations, e.g., poor solubility and adverse effects such as prolongation of the QT interval.
Simisola Ayodele   +4 more
doaj   +1 more source

Home - About - Disclaimer - Privacy